Systemic therapies for non-small-cell lung cancer (NSCLC) are increasingly guided by tumour biomarker results, such as protein expression markers (program death ligand–1 [PDL-1]) and molecular profiling [1,2,3]. Here, CD274 is linked to non-small cell lung carcinoma.